Enlivex (ENLV) Income towards Parent Company (2014 - 2025)
Enlivex (ENLV) posted quarterly Income towards Parent Company of -$4.9 million for Q4 2025, down 5.23% year-over-year from -$5.2 million in Q4 2024, and down 44.15% quarter-over-quarter from -$3.4 million in Q3 2025.
Enlivex (ENLV) Income towards Parent Company (2014 - 2025) Analysis & Trends
Enlivex's Income towards Parent Company history runs 12 years deep, the most recent figure standing at -$4.9 million for Q4 2025.
- In Q4 2025, Income towards Parent Company fell 5.23% year-over-year to -$4.9 million; the TTM figure through Dec 2025 stood at -$15.8 million (up 9.52% YoY), while the FY2025 annual figure was $1.2 billion, up 10787.03% from the prior year.
- Income towards Parent Company for Q4 2025 stood at -$4.9 million, down from -$3.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was $2.1 million in Q2 2021, with the low at -$12.7 million in Q4 2023.
- The 5-year median for Income towards Parent Company is -$4.7 million (2024), against an average of -$5.2 million.
- The sharpest annual moves came in 2021 and 2022: Income towards Parent Company soared 277.53% in 2021, then tumbled 787.28% in 2022.
- Enlivex's Income towards Parent Company stood at -$8.2 million in 2021, then declined by 3.04% to -$8.5 million in 2022, then sank by 49.55% to -$12.7 million in 2023, then soared by 63.27% to -$4.6 million in 2024, then retreated by 5.23% to -$4.9 million in 2025.
- Business Quant data shows ENLV's Income towards Parent Company at -$4.9 million in Q4 2025, -$3.4 million in Q3 2025, and -$3.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.89 Mn |
| Sep 30, 2025 | -3.39 Mn |
| Jun 30, 2025 | -3.64 Mn |
| Mar 31, 2025 | -3.90 Mn |
| Dec 31, 2024 | -4.65 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Jun 30, 2024 | -3.93 Mn |
| Mar 31, 2024 | -4.67 Mn |
| Dec 31, 2023 | -12.66 Mn |
| Sep 30, 2023 | -4.64 Mn |
| Jun 30, 2023 | -6.42 Mn |
| Mar 31, 2023 | -7.25 Mn |
| Dec 31, 2022 | -8.46 Mn |
| Sep 30, 2022 | -5.89 Mn |
| Jun 30, 2022 | -10.83 Mn |
| Mar 31, 2022 | -6.41 Mn |
| Dec 31, 2021 | -8.21 Mn |
| Sep 30, 2021 | 857,000.00 |
| Jun 30, 2021 | 2.06 Mn |
| Mar 31, 2021 | -2.79 Mn |